Company / Capital Expenditures
Adaptive Biotechnologies Corp Capital Expenditures History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$3.0M
FY2025
5-year range
$3.0M / $61.7M
FY2021-FY2025
Trend
-19.2%
vs FY2024
Sector context
#87 of 194
Health Care
What the data says
At $3M, Adaptive Biotechnologies Corp's capital expenditures ranks #87 of 194 in the Health Care sector. Capital Expenditures has declined for 4 consecutive years, from $62M in FY2021 to $3M in FY2025.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of -30.9%.
Declined from $11M to $3M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -43.4%
- 5-Year CAGR
- -30.9%
- 10-Year CAGR
- -
Sector benchmark
#87 of 194 in Health CareTop 45% of 194This company $3.0M Sector average $117.5M
▼
-97.5% below sector average
Key checks
Key Insights
- Adaptive Biotechnologies Corp's capital expenditures has declined for 4 consecutive years.
- 5-year CAGR of -30.9%, indicating a declining trend.
- In FY2025, capital expenditures decreased 19.2% year-over-year.
- Ranks #87 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.45 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.0M | -19.2% |
| FY2024 | $3.7M | -65.7% |
| FY2023 | $10.7M | -34.6% |
| FY2022 | $16.3M | -73.5% |
| FY2021 | $61.7M | +228.4% |
| FY2020 | $18.8M | +67.9% |
| FY2019 | $11.2M | +77.8% |
| FY2018 | $6.3M | +160.2% |
| FY2017 | $2.4M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026